Adagio Medical, a medical device company with a focus on treating cardiac arrhythmias, has been formally notified by the Nasdaq Stock Market that it is not in compliance with the minimum bid price requirement for continued listing. The notice, issued on 13th June 2024, indicates that the company's common stock has traded below the mandatory minimum bid price of $1.00 per share for 30 consecutive business days.
Under Nasdaq Listing Rule 5550(a)(2), companies listed on the exchange must maintain a minimum bid price of $1.00 per share. Adagio Medical now has a period of 180 calendar days, which extends until 10th December 2024, to regain compliance with this standard. To satisfy the requirement, the company's common stock must achieve a closing bid price of $1.00 or higher for at least ten consecutive business days within this compliance period.
Should Adagio Medical fail to meet this criterion by the initial deadline, it may be eligible for an additional 180-day compliance period, provided it meets other listing requirements, including market value of publicly held shares and all other applicable standards for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement. The company would also need to formally notify Nasdaq of its intention to cure the deficiency during this second compliance period.
The receipt of such a notice is a standard procedure for companies whose share prices fall below the Nasdaq threshold and does not immediately result in delisting. However, it does highlight potential challenges for the company, which could include reduced investor confidence and difficulties in attracting new investment or raising capital through equity offerings. Adagio Medical has stated its intention to monitor its share price and consider available options to regain compliance.
Adagio Medical is known for its cryoablation system, which is designed to treat atrial fibrillation and other complex cardiac arrhythmias. The company's technology aims to provide more effective and durable treatment options for patients suffering from these conditions. The long-term implications of this notice for the company will depend on its ability to improve its share price performance and maintain its listing on Nasdaq.
Source: Adagio Medical